免疫法/（±）-SLV319/10mg 50mg 100mg/MC1362
市场价：
¥6400.00
美元价：
3200.00
产品分类：
特色ELISA试剂盒
公司分类：
Specialty_ELISA_kits
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
(±)-SLV319
- Catalog No.：MC1362
- Data Sheet
- MSDS
- Support
- Description
- References ( 0 )
- Protocol
- CasNo：
- 362519-49-1
- MolecularFormula：
- C23H20Cl2N4O2S
- Purity：
- >98%
- Target：
- Cannabinoid Receptor
- IC50：
- IC50: 22 nM (CB-1)[1]; Ki: 7.8 nM (CB-1)[2]
- In Vitro：
- Cannabinoid receptor 1 (CB1R) antagonists appear to be promising drugs for the treatment of obesity, however, serious side effects have hampered their clinical application. Ibipinabant is a new, potent [Ki (CB1)=7.8 nM] and selective [Ki (CB2)=7.943 nM] CB1 antagonist [pA2 for arachidonic acid release in CHO cells=9.9] with in vitro pharmacological characteristics similar to rimonabant including inverse agonism and brain penetrance[3].
- In Vivo：
- Ibipinabant (3 mg/kg) reduces unfasted glucose to a significantly greater degree than rimonabant at the same dose on days 17, 28 and 38. Chronic treatment with ibipinabant significantly attenuates the progression of diabetes in ZDF rats, blunting the increase in blood glucose and HbA1c over time. Ibipinabant also reduces the hyperinsulinemia apparent at 6-8 weeks of age and attenuates the dramatic reduction in insulin levels observed 1-2 weeks later[3].
- Fields：
- (±)-SLV 319 is a potent and selective CB1 receptor antagonist (Ki = 7.8 nM). Exhibits 1000-fold selectivity for CB1 over CB2 receptors. IC50: 22 nM (CB-1)[1]; Ki: 7.8 nM (CB-1)[2]
- Specificity：
- Target: Cannabinoid Receptor. Fields: (±)-SLV 319 is a potent and selective CB1 receptor antagonist (Ki = 7.8 nM). Exhibits 1000-fold selectivity for CB1 over CB2 receptors. IC50: 22 nM (CB-1)[1]; Ki:
- Source：
- Rabbit
- Dilution：
- IC50: 22 nM (CB-1)[1]; Ki: 7.8 nM (CB-1)[2]
- Concentration：
- >98%
- Storage Stability：
- 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO
- Other Name：
- SLV 319,SLV-319
- MolecularWeight(Da)：
- 487.4
- References：
- [1]. Chorvat RJ, et al. JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities.
- June 19-2018
- WESTERN IMMUNOBLOTTING PROTOCOL
- June 19-2018
- IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL
- June 19-2018
- IMMUNOFLUORESCENCE PROTOCOL
- September 08-2020
- FLOW-CYTOMEYRT-PROTOCOL
- July 13-2018
- CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN
- July 13-2018
- CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN
- July 13-2018
- CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN
- July 13-2018
- Antibody-FAQs
- Products Images
品牌介绍
ImmunowayImmunoWay Biotechnology，我们的使命是帮助世界各地的生命科学研究人员通过更好的产品和服务简化和加速他们的研究。我们专注于开发用于免疫学和细胞学检测的创新和可靠的产品。我们一直是开发高质量ELISA试剂盒，代谢检测试剂盒，抗体和抗体/蛋白质微阵列的先驱，参与癌症，细胞凋亡，细胞生长和信号转导。ImmunoWay Biotechnology，我们的使命是通过更好的产品和服务帮助世界各地的生命科学研究者简化和加速他们的研究。我们专注于开发创新和可靠的产品，用于免疫学和细胞学检测。我们一直是开发涉及癌症，细胞凋亡，细胞生长和信号转导的高质量ELISA试剂盒，代谢测定试剂盒，抗体和抗体/蛋白质微阵列的先驱。
品牌分类
\Elisa试剂盒\
联络我们
